BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26191134)

  • 1. Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
    Garcia PV; Apolinário LM; Böckelmann PK; da Silva Nunes I; Duran N; Fávaro WJ
    Int J Clin Exp Pathol; 2015; 8(5):4427-43. PubMed ID: 26191134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
    BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
    Fávaro WJ; Socca EAR; Böckelmann PK; Reis IB; Garcia PV; Durán N
    Med Oncol; 2022 Jan; 39(2):24. PubMed ID: 34982270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
    de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
    J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.
    Dias QC; Nunes ID; Garcia PV; Favaro WJ
    Int Braz J Urol; 2016; 42(5):942-954. PubMed ID: 24893914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
    Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
    Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
    Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
    Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor activation: a prospective therapeutic target for bladder cancer?
    Mizushima T; Tirador KA; Miyamoto H
    Expert Opin Ther Targets; 2017 Mar; 21(3):249-257. PubMed ID: 28064545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
    Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
    Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
    Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
    Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
    Lupi LA; Delella FK; Cucielo MS; Romagnoli GG; Kaneno R; Nunes IDS; Domeniconi RF; Martinez M; Martinez FE; Fávaro WJ; Chuffa LGA
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31861351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
    Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
    BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
    Xiao Z; Mak A; Koch K; Moore RB
    BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
    Ohadian Moghadam S; Nowroozi MR
    Scand J Immunol; 2019 Dec; 90(6):e12818. PubMed ID: 31448424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
    Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
    Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
    Naderi A; Liu J
    Cancer Lett; 2010 Dec; 298(1):74-87. PubMed ID: 20605569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.